The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NICHD

Contract Value

Not provided

Codes & Classification
Solicitation Number

RFA-DK-23-017_RFA-DK-23-018

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

Q999

Additional Details
Set Aside

None

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS), has issued a Special Notice seeking industry partners for collaborative clinical research focused on therapeutics, diagnostics, or devices targeting childhood cholestatic liver diseases. This initiative is anchored in the ongoing efforts of the Childhood Liver Disease Research and Education Network (ChiLDReN), a multi-center consortium funded by NIDDK, which encompasses ten clinical sites across the United States and a scientific data coordinating center. **Purpose and Scope** The primary objective of this collaboration opportunity is to advance the understanding and treatment of rare pediatric liver diseases that result in cholestasis. These include, but are not limited to, biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis. The scope of the collaboration encompasses the provision and evaluation of novel therapeutic agents, diagnostic markers, biomarkers, and medical devices within the context of NIH-sponsored multi-center clinical trials and ancillary studies. **Key Requirements and Expected Deliverables** Industry collaborators are expected to contribute innovative products—therapeutics, diagnostics, or devices—that have already undergone Phase I human trials. The collaboration will leverage ChiLDReN’s extensive, well-characterized patient cohorts and ongoing longitudinal studies to evaluate the natural history, pathogenesis, diagnosis, genetic and molecular underpinnings, and clinical outcomes of these diseases. Specific research interests include: - Assessment of serum and imaging biomarkers for disease activity, fibrosis, and therapeutic response. - Controlled clinical trials of proprietary drugs or devices as potential diagnostics or treatments. - Evaluation of novel newborn or infant screening techniques for early detection. - Investigation of noninvasive imaging modalities (e.g., elastography, MRI, molecular imaging). - Use of cytokine assays as markers of disease activity and therapeutic response. Prospective collaborators must submit a detailed Capability Statement (maximum 10 narrative pages, excluding appendices) addressing the following: 1. Description of the proposed therapeutic, diagnostic, or device, including prior Phase I human data. 2. Methodological approach for clinical investigation in the relevant patient populations. 3. Plan for timely provision of sufficient quantities of the product for study duration. 4. Laboratory testing requirements, including assays and specimen needs. 5. Description of necessary core facilities and interactions. 6. Human dosing and pharmacokinetic data for novel therapeutics. 7. Adverse event profile. 8. Data privacy and confidentiality practices. 9. (Optional) Outcome measures of interest. 10. Additional resources to be committed (e.g., equipment, personnel, funding under a CRADA). 11. Affirmations regarding regulatory cross-referencing, protocol adherence, data sharing, publication, and compliance with PHS intellectual property policies. **Contracting Entity and Contact Information** The contracting entity is the National Institutes of Health (NIH), specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), located in Bethesda, Maryland. The primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology), and the Product Service Code is Q999. Key contacts for this opportunity are: - **Scientific Inquiries:** - Dr. Edward Doo, Director, Liver Diseases Research Program Email: [email protected] | Phone: 301-451-4524 - Dr. Katrina Loh, Director, Pediatric Gastrointestinal and Liver Diseases Email: [email protected] | Phone: 301-827-1079 - **Collaboration and Intellectual Property:** - Agnes Rooke, JD, Technology Advancement Office Email: [email protected] | Phone: 301-451-6072 Capability Statements should be submitted to the NIDDK NOO Coordinator at [email protected]. **Procurement Type and Special Considerations** This is a Special Notice for collaborative research, not a traditional procurement or grant opportunity. No federal funds will be provided to selected organizations; instead, the collaboration is structured to leverage industry resources and expertise in partnership with the ChiLDReN network. Collaborators must be prepared to attend a ChiLDReN Steering Committee meeting (at their own expense) to discuss their proposals. All collaborations will be governed by agreements adhering to PHS intellectual property policies, and results will be published in accordance with NIH requirements. **Constant Elements Over Contract Lifecycle** Throughout the collaboration, the focus will remain on advancing clinical research for childhood cholestatic liver diseases, utilizing ChiLDReN’s established infrastructure and patient cohorts. The expectation for data sharing, publication, and adherence to NIH and PHS policies will persist. The place of performance is Bethesda, Maryland, with the potential for multi-center clinical trial activities across the ChiLDReN network. **Summary for Contractors** This opportunity is well-suited for commercial organizations with advanced-stage therapeutics, diagnostics, or devices relevant to rare pediatric liver diseases, seeking to collaborate with a leading NIH-funded research network. The collaboration offers access to robust clinical research infrastructure and patient populations, with the potential for significant scientific and clinical impact. Interested parties must be able to provide regulatory-ready products, commit resources, and engage in transparent data sharing and publication practices. For full details and submission instructions, refer to the official notice at [SAM.gov](https://sam.gov/opp/c7b47e26151e40f38804ba34321b7179/view) or the NIDDK technology development site.